| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/20/2005 | US20050013855 siRNA associated with lipid precipitate; in vivo delivery to cytosol |
| 01/20/2005 | US20050013854 Novel encochleation methods, cochleates and methods of use |
| 01/20/2005 | US20050013853 Topical formulation of cyclic psychotropic agent; dermatological disease, disorder and/or pathology; minimizing central nervous system side effects |
| 01/20/2005 | US20050013852 Rapid release, water permeable self adhesive polymer matrix system; photodynamic therapy and/or diagnosis of skin lesions |
| 01/20/2005 | US20050013848 Fat or oil composition |
| 01/20/2005 | US20050013847 Delivery systems of homogeneous, thermoreversible alginate films |
| 01/20/2005 | US20050013836 Antimicrobial flush solutions |
| 01/20/2005 | US20050013835 Stable non-dihydrate azithromycin oral suspensions |
| 01/20/2005 | US20050013834 Pharmaceutical formulations comprising ketoconazole |
| 01/20/2005 | US20050013808 Nitroreductase enzymes |
| 01/20/2005 | US20050013794 Mixture of addition polymer and polyguanidine microbiocides |
| 01/20/2005 | US20050013792 Dispersion containing ion exchange matrix drug complex; shelf life |
| 01/20/2005 | US20050013791 Cytokine-inducing material and cytokine-inducing instrument |
| 01/20/2005 | US20050013783 Prevention and/or treatment of erythema induced by exposure to ultraviolet or solar radiation; topical |
| 01/20/2005 | US20050012115 Ion sensitive field effect transistor and method for producing an ion sensitive field effect transistor |
| 01/20/2005 | US20050011468 Use of methylnaltrexone in treating gastrointestinal dysfunction in equines |
| 01/20/2005 | DE20221087U1 Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen Transdermal therapeutic system with fentanyl and related substances |
| 01/20/2005 | DE10339864A1 Coffein enthaltende Tablette Caffeine-containing tablet |
| 01/20/2005 | DE10330243A1 Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von Arzneimitteln zur äusserlichen Behandlung der Neurodermitis Use of products derived from extremophilic bacteria osmolytes for the production of drugs for external treatment of atopic dermatitis |
| 01/20/2005 | DE10329716A1 Verbesserung der Schlupffähigkeit bei eierlegenden Tieren Improving hatchability in oviparous animals |
| 01/20/2005 | DE10329457A1 New 1,2-bis-phenylaminocarbonyl-pyrrolidine derivatives, useful for treating or preventing e.g. thrombosis, myocardial infarct and arteriosclerosis, are inhibitors of coagulation factor Xa |
| 01/20/2005 | DE10329386A1 Aqueous solution containing opipramol salt, useful for treating depression, also includes a sugar alcohol or synthetic sweetener to improve taste and chemical stability, particularly color |
| 01/20/2005 | CA2838411A1 Methods of treating acne and rosacea with galvanic generated electricity |
| 01/20/2005 | CA2569537A1 Use of betaine for treating arteritis |
| 01/20/2005 | CA2532833A1 Use of whey permeate for the treatment of metabolic syndrome |
| 01/20/2005 | CA2532828A1 Combinations of vasoactive agents, their use in the pharmaceutical and cosmetic field, and formulations containing them |
| 01/20/2005 | CA2532825A1 Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions |
| 01/20/2005 | CA2532068A1 Pyrrole-2, 5-dithione derivatives as liver x receptor modulators |
| 01/20/2005 | CA2532056A1 Pyrrole-2, 5-dione derivatives as liver x receptor modulators |
| 01/20/2005 | CA2532019A1 Sirna expression system |
| 01/20/2005 | CA2531861A1 Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor |
| 01/20/2005 | CA2531859A1 Benzimidazole derivatives as raf kinase inhibitors |
| 01/20/2005 | CA2531856A1 Benzimidazole carboxamides as raf kinase inhibitors |
| 01/20/2005 | CA2531790A1 Compound having anti-hcv action and its production method |
| 01/20/2005 | CA2531787A1 Sulfonamide derivatives as 5ht7 receptor antagonists |
| 01/20/2005 | CA2531759A1 Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors |
| 01/20/2005 | CA2531757A1 Benzofuran derivatives and their use in the treatment of microbial infections |
| 01/20/2005 | CA2531751A1 Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 01/20/2005 | CA2531749A1 N-(heterobicycloalkanes)-subtituted indoles- or heteroderivatives thereof |
| 01/20/2005 | CA2531643A1 Combination therapy |
| 01/20/2005 | CA2531636A1 Compositions for activating the infiltration activity of dendritic cells and immunopotentiating agents |
| 01/20/2005 | CA2531629A1 Medicinal composition containing nf-.kappa.b decoy for treating and preventing respiratory diseases and method of using the same |
| 01/20/2005 | CA2531512A1 Organosilicon compounds and their use |
| 01/20/2005 | CA2531511A1 Silicon compounds and their use |
| 01/20/2005 | CA2531510A1 Spiro '1-azabicyclo '2.2.2!octan-3,5'-oxazolidin-2'one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor |
| 01/20/2005 | CA2531485A1 Malonamide derivatives |
| 01/20/2005 | CA2531418A1 Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds |
| 01/20/2005 | CA2531417A1 Herbal compositions for the treatment and prevention of prostate disorders |
| 01/20/2005 | CA2531407A1 Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients |
| 01/20/2005 | CA2531396A1 Dispenser with reservoir containing a drug of abuse |
| 01/20/2005 | CA2531283A1 Specific human antibodies |
| 01/20/2005 | CA2531186A1 Use of an antioxidant in a dermatological and/or cosmetic composition |
| 01/20/2005 | CA2530838A1 Topical antiviral therapeutic and prophylactic treatment of adenoviruses and their associated diseases |
| 01/20/2005 | CA2530780A1 Tacrine derivatives as inhibitors of acetylcholinesterase |
| 01/20/2005 | CA2530737A1 Cck-1 receptor modulators |
| 01/20/2005 | CA2530589A1 Arylmethyl triazolo and imidazopyrazines as c-met inhibitors |
| 01/20/2005 | CA2530538A1 Thiophenylaminoimidazolines as prostaglandin i2 antagonists |
| 01/20/2005 | CA2530455A1 Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases |
| 01/20/2005 | CA2530450A1 5-substituted quinazolinone derivatives |
| 01/20/2005 | CA2530312A1 Arylamine-substituted quinazolinone compounds |
| 01/20/2005 | CA2530193A1 Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
| 01/20/2005 | CA2530182A1 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
| 01/20/2005 | CA2530048A1 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
| 01/20/2005 | CA2530025A1 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
| 01/20/2005 | CA2530006A1 Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease |
| 01/20/2005 | CA2529994A1 N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
| 01/20/2005 | CA2529739A1 Aspartyl protease inhibitors |
| 01/20/2005 | CA2529598A1 Stable freeze-dried pharmaceutical formulation of tetrodotoxin |
| 01/20/2005 | CA2529461A1 Novel solid pharmaceutical composition comprising amisulpride |
| 01/20/2005 | CA2529323A1 Tetracyclic compounds as c-met inhibitors |
| 01/20/2005 | CA2529294A1 Oxazolidinone antibiotics and derivatives thereof |
| 01/20/2005 | CA2529293A1 Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof |
| 01/20/2005 | CA2529292A1 Oxazolidinone antibiotics and derivatives thereof |
| 01/20/2005 | CA2528626A1 Indoles useful in the treatment of inflammation |
| 01/20/2005 | CA2528587A1 .beta.-lactamase inhibitors and methods of use thereof |
| 01/20/2005 | CA2528336A1 Tetrahydrocarbazole derivatives and their pharmaceutical use |
| 01/20/2005 | CA2528148A1 Coumarin derivatives for the treatment of ophthalmic disorders |
| 01/20/2005 | CA2528144A1 Method for treating acute pancreatitis |
| 01/20/2005 | CA2528120A1 Methods for treating lentivirus infections |
| 01/20/2005 | CA2526725A1 Mch antagonists for the treatment of obesity |
| 01/19/2005 | EP1498493A1 Method of examining allergic disease |
| 01/19/2005 | EP1498411A1 Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient |
| 01/19/2005 | EP1498406A1 Novel hydronaphthalene compounds, prepared by a rhodium catalysed ring opening reaction in the presence of phosphine ligand |
| 01/19/2005 | EP1498150A1 Delivery of solid drug compositions |
| 01/19/2005 | EP1498143A1 Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
| 01/19/2005 | EP1498141A1 Stable non-dihydrate azithromycin oral suspensions |
| 01/19/2005 | EP1498140A2 Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders |
| 01/19/2005 | EP1498139A1 Novel thrombomodulin expression promoters |
| 01/19/2005 | EP1498138A1 Preventives for hiv infection |
| 01/19/2005 | EP1498137A1 Remedy for lung cancer |
| 01/19/2005 | EP1498128A1 Medicinal compositions containing phtocrosslinkable chitosan derivative |
| 01/19/2005 | EP1498127A1 Use of antitumor indolopyrrolocarbazole derivative and other anticancer agent in combination |
| 01/19/2005 | EP1498126A1 Neurotrophic factor production accelerator |
| 01/19/2005 | EP1498125A1 Use of compounds having ccr antagonism |
| 01/19/2005 | EP1498124A2 The use of inhibitors of the renin-angiotensin system |
| 01/19/2005 | EP1498123A1 Emulsifying systems containing azetidine derivatives |
| 01/19/2005 | EP1498122A1 Semi-solid systems containing azetidine derivatives |
| 01/19/2005 | EP1498121A1 Use of specific cyclolignans |
| 01/19/2005 | EP1498120A1 Semi-solid formulations for the oral administration of taxoids |
| 01/19/2005 | EP1498119A1 Use of conjugated linoleic acid for treating colds |